GSK ‘respectfully disagrees’ with Zantac litigation ruling in California

In response to yesterday’s Sargon ruling by the California state court in respect of the Goetz case, GSK plc issued the following statement: "GSK respectfully disagrees with this ruling by the California state court. Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. The litigation is still at an early stage and yesterday’s decision relates only to the question of whether the plaintiff’s experts can testify at trial in the Goetz case. It does not mean that the Court agrees with plaintiff’s experts’ scientific conclusions or their litigation-driven science. GSK will press additional defences and the plaintiff still needs to prove his case at trial. This ruling does not affect other state cases or the December 2022 Daubert ruling made in the federal Multi-District Litigation."